Recently, it was demonstrated that blockade of IL‐6 trans‐signalling by anti‐IL‐6R antibodies or recombinant sgp130 protein bound to the Fc region of human IgG1 might not only partly ameliorate the development of IBD but also the CAC progression (Figure 5E).108. Here, IL6 is linked to inflammatory bowel disease.